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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.024Histopathological classiﬁcation of human prostate cancer (PCA) relies on the morphological assessment of
tissue specimens but has limited prognostic value. To address this deﬁciency, we performed comparative
transcriptome analysis of human prostatic acini generated in a three-dimensional basement membrane that
recapitulates the differentiated morphological characteristics and gene expression proﬁle of a human
prostate glandular epithelial tissue. We then applied an acinar morphogenesisespeciﬁc gene proﬁle to two
independent cohorts of patients with PCA (total nZ 79) and found that those with tumors expressing this
proﬁle, which we designated acini-like tumors, had a signiﬁcantly lower risk of postoperative relapse
compared with those tumors with a lower correlation (hazard ratio, 0.078; log-rank test P Z 0.009).
Multivariate analyses showed superior prognostic prediction performance using this classiﬁcation system
compared with clinical criteria and Gleason scores. We prioritized the genes in this proﬁle and identiﬁed
programmed cell death protein 4 (PDCD4) and Kruppel-like factor 6 (KLF6) as critical regulators and surrogate
markers of prostatic tissue architectures, which form a gene signature that robustly predicts clinical prog-
nosis with a remarkable accuracy in several large series of PCA tumors (total nZ 161; concordance index,
0.913 to0.951). Thus, by exploiting the genomicprogramassociatedwithprostate glandular differentiation,
we identiﬁed acini-like PCAand relatedmolecularmarkers that signiﬁcantly enhanceprognostic predictionof
human PCA. (Am J Pathol 2013, 182: 363e374; http://dx.doi.org/10.1016/j.ajpath.2012.10.024)Supported by the National Health Research Institutes Intramural
Research Program grant (CA-100-PP-19 to K.K.-C.T.), National Science
Council (NSC) grant (96-2321-B-038-004 to K.K.-C.T.), National Core
Facility Program for Biotechnology Grants of NSC (NSC 100-2319-B-400-
001), an NSC grant (99-2218-E-168-004 to M.T.-L.L.), Department of
Health grant (DOH100-TD-C-111-004 to K.K.-C.T.), and National Cancer
Institute grants (P50 CA 58207 and R01 CA140663-01A2 to V.M.W.).
C.-R.L. and J.J.-M.S. contributed equally to this work.Prostate cancer (PCA) is a leading cause of cancer-related
death in men. For early-stage localized prostate cancer,
radical prostatectomy offers the best opportunity to eradicate
the disease. However, approximately 15% to 30% of patients
with localized disease at diagnosis develop recurrence within
5 to 10 years, and most of these patients subsequently show
poor therapeutic outcome.1,2 Strategies to stratify the initially
diagnosed disease into higher-risk patients with PCA would
permit a more personalized targeted treatment strategy that
could prevent recurrence. Moreover, a deeper understanding
of the pathomolecular mechanisms underlying disease re-
currence would help to identify new therapeutic targets.stigative Pathology.
.Such as most glandular cancers, the malignant trans-
formation of prostatic epithelium involves a gradual loss of
cell adhesion and normal glandular architecture.3e7 Loss of
the ability to form tissue architectures by prostate epithelial
Li et alcells has been functionally linked to increased tumorige-
nicity.5 Because human PCA frequently displays consider-
able intratumoral heterogeneity in glandular differentiation,
this spectrum of tissue morphological characteristics is
widely used to classify PCA pathological features according
to metrics, such as the Gleason grading system.7 Large-
scale clinical studies have established the degree of glan-
dular differentiation as a reasonable determinant to assess
the clinical behavior of PCA. Speciﬁcally, poorly differ-
entiated, higheGleason grade tumors are typically associ-
ated with a higher probability of tumor recurrence, and
patients with these tumors often show poorer prognosis.8,9
Nevertheless, this morphological characteristicebased clas-
siﬁcation system is only modestly prognostic and does not
allow for risk stratiﬁcation of PCA with similar histopath-
ological characteristics.
Tumor classiﬁcation based solely on tissue architecture has
failed to provide functional or mechanistic insights into
tumor variability. Accordingly, there is a critical need for
molecularly based diagnostic assays that can increase the
accuracy of disease prognosis and clinical outcome in PCA.
Recently, high-throughput genomic proﬁling techniques
have been applied to molecularly characterize several
human malignancies, including PCA, with encouraging
success.10e15 The profound prognostic utility of these
genomic markers underlines the intrinsic molecular charac-
teristic of tumors as a crucial determinant to their clinical
behavior and has laid the framework for personalized medi-
cine. Genomic tools have also been used to molecularly
deﬁne tumor phenotypes or subtypes. For example, transcript
proﬁling of human PCA has supported the existence of
distinct tumor subclasses that are associated with distinct
tumor grades and stage.16 Furthermore, gene expression
patterns that correlate with Gleason score and distinguish
low- from high-grade PCA have been described.6,17 These
molecular patterns of PCA are instructive, and they can help
to characterize tumor characteristics. However, the mecha-
nisms underlying the genesis of these molecular variations in
human PCA remain to be further explored.
Knowledge-based approaches offer an opportunity to
identify more rational markers or classiﬁcation systems that
beneﬁt clinical decision making and therapeutic advance-
ment. Such approaches have been used to establish the
prognostic roles of gene proﬁles associated with tumor
progenitor cells, stromal activation, or tissue differentiation
in several types of solid tumors.18e21 Whether a similar
approach could be applied to improve the prognostic
prediction of PCA has yet to be determined. In this study,
we exploited the experimental merits of a physiologically
relevant model of tissue organization, thereby identifying
a gene expression program that associates with prostate
epithelial acinar morphogenesis. We constructed a gene
signature that identiﬁes a subset of more differentiated
acini-like human PCAs with a favorable outcome. Relative
to clinical criteria and Gleason score, this constructed, bio-
logically informed molecular classiﬁcation scheme displayed364a more robust and accurate ability to predict the prognosis of
human PCA. Uniquely, this signature consists of gene
markers whose gene expression pattern depends on tissue
architecture. The strength of this signature was validated as
having strong prognostic value using several target genes as
surrogate markers of tissue differentiation. Thus, to our
knowledge, our results provide the ﬁrst example of a bio-
logically tractable and clinically instructive molecular
signature for PCA that is based on criteria informed by
tissue morphological characteristics.
Materials and Methods
Cell Culture and Staining
Primary human prostate epithelial cells (PrECs; Clonetics
Cell Systems; Lonza, Walkersville, MD) were propagated
on tissue culture plastics in chemically deﬁned medium,
according to the manufacturer’s instructions. RWPE-1 cells
(ATCC, Manassas, VA) were maintained in keratinocytee
serum-free medium (Invitrogen, Carlsbad, CA) supple-
mented with bovine pituitary extract, 10 ng/mL epidermal
growth factor, and 0.5% penicillin-streptomycin (Invi-
trogen).22 LNCaP, DU-145, and PC-3 cells (ATCC) were
maintained in RPMI 1640 medium (for LNCaP cells) or
Dulbecco’s modiﬁed Eagle’s medium (for DU-145 and
PC-3 cells; Invitrogen) supplemented with 10% fetal
bovine serum and 0.5% penicillin-streptomycin. The cells
were embedded and grown within a thick layer of three-
dimensional (3D) reconstituted basement membrane (rBM)
gel (Matrigel; BD Biosciences, San Jose, CA), as previously
described.23 Whole culture immunoﬂuorescent staining was
performed as previously described.24 Confocal imaging was
performed using a Nikon Digital Eclipse C1 confocal
microscope system (Nikon, Tokyo, Japan). The antibodies
used include rat anti-a6 integrin (clone GoH3; Millipore)
and mouse anti-GM130 (clone 35; BD Biosciences). Cell
nuclei were counterstained with Hoechst 33342 or DAPI
(Invitrogen).
Gene Expression Proﬁling
Total RNA samples were extracted from cells that were
embedded and cultivated within the 3D rBM gels for
different lengths of time (36 to 48 hours or 7 to 8 days) using
TRIzol (Invitrogen) and then puriﬁed using an RNeasy
minikit and DNase treatment (Qiagen, Valencia, CA).
Experiments were performed in triplicate. Whole-genome
gene expression analysis was performed on an Affymetrix
Human Genome U133A 2.0 Plus GeneChip platform,
according to the manufacturer’s protocol (Affymetrix, Santa
Clara, CA). The hybridization intensity data were processed
using the GeneChip Operating software (Affymetrix), and
the genes were ﬁltered based on the Affymetrix P/A/M ﬂags
to retain those that were present in all three of the samples in
at least one of the experimental conditions. A false-discoveryajp.amjpathol.org - The American Journal of Pathology
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genes within a comparison group. The gene expression data
have been deposited in the National Center for Biotech-
nology Information’s Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo; accession number GSE30304).Quantitative Real-Time RT-PCR Analysis
Total RNA (1.0 mg) extracted from the 3D culture was
used as a template for cDNA synthesis using Moloney
Murine Leukemia Virus Reverse Transcriptase (Promega,
Madison, WI). cDNA (100 ng) was used as a template for
PCR ampliﬁcation using the LightCycler FastStart DNA
MASTERPLUS SYBR Green I Kit, and quantitative real-
time RT-PCR analysis was performed on the ampliﬁed
RNA using the LightCycler FastStart DNA MASTER-
PLUS SYBR Green I Kit (Roche Diagnostics GmbH,
Mannheim, Germany). Oligonucleotide primers were
designed using Primer Bank (http://pga.mgh.harvard.edu/
primerbank/index.html, last accessed June 10, 2012). The
sequences are available on request.Hierarchical and Functional Gene Clustering
We median centered the genes identiﬁed from the gene
expression proﬁling experiments and performed average
linkage clustering using Cluster software version 2.11 and
TreeView software version 1.60 (Eisen Lab, University of
California, Berkeley). For functional clustering, the selected
genes were uploaded to DAVID (http://david.abcc.ncifcrf.
gov, last accessed March 28, 2012) and a ranked list of
functional annotations was executed and generated by the
system. We surveyed the functional annotations according to
the gene ontology biological process, with P < 0.05, and the
top 10 functional annotations, along with their associated
genes, were displayed in a diagram output using Cytoscape
software (http://www.cytoscape.org, last accessed March 28,
2012). Ingenuity Pathway Analysis (Ingenuity Systems,
Redwood City, CA) was used to search for the enriched
biological networks and functions of the selected genes.Gene Expression Data Sets of Human PCA
The tumor transcriptome data of 50 patients with PCA who
underwent radical prostatectomy at Brigham and Women’s
Hospital (BWH cohort; Boston, MA) and the associated
clinical information were previously reported and were
kindly provided by Massimo Loda (Dana-Farber Cancer
Institute, Boston).10 Gene expression proﬁles of PCA and
associated clinical information from 29 patients who under-
went radical prostatectomy at Stanford University (Stanford,
CA), Karolinska Institute (Solna, Sweden), and Johns Hop-
kins University (Baltimore, MD) (the SU/KI/JHU cohort)
were downloaded from Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo; accession number GSE3933).16The American Journal of Pathology - ajp.amjpathol.orgMeasurement of Similarity between Gene Expression
Proﬁles
To measure the degree of resemblance between the gene
expression proﬁles of a clinical tumor specimen and
a prostatic organoid, we mapped the selected probe sets
from different microarray platforms to the same Entrez-gene
IDs and then normalized and mean centered the probe
hybridization intensity levels (for Affymetrix microarrays)
or ﬂuorescence ratios (for cDNA microarrays) of each of
the selected probes across all tumors or the prostate archi-
tectures. For each tumor, we calculated the Pearson’s
correlation coefﬁcient between the tumor and the org-
anoid based on the expression proﬁle of the selected gene
probes.
Construction of Prognostic Predictors
To identify, from the differentially expressed genes, a set of
gene markers that optimally predicted risk of recurrence
after radical prostatectomy in human PCA, we used
a previously described supervised approach with modiﬁca-
tions.25 Brieﬂy, for each gene, univariate Cox regression
analysis was used to measure the correlation between the
expression level of the gene (on a log2 scale) and the length
of relapse-free survival of the patients with PCA in the
BWH cohort. We constructed 1000 bootstrap samples of the
patients in the cohort and performed Cox regression anal-
ysis on each of the samples. We then determined an esti-
mated P value and an estimated standardized Cox
regression coefﬁcient for each gene by calculating the
median P values and the median Cox coefﬁcient of the
1000 bootstrap samples, respectively. To ensure the
consistency of our model, we selected the genes whose
expressional changes during prostatic cystic differentiation
were associated with the expected positive (for genes with
higher expression levels in cellular aggregates) or negative
(for genes up-regulated in prostatic cysts) risk of relapse, as
determined by the estimated standardized Cox regression
coefﬁcient. The selected genes were then rank ordered
according to the estimated P values, and multiple sets of
genes were generated by repeatedly adding one more gene
each time from the top of the descendingly ranked list,
starting from the ﬁrst three top-ranked genes. We then
calculated a recurrence score (Equation 1) to measure the
risk of relapse of a patient for a gene set:
Recurrence scoreZ
Xk
iZ3
bixi ð1Þ
where k is the number of probes in the probe set, bi is the
standardized Cox regression coefﬁcient for the ith probe,
and xi is the log2 expression level for the ith probe.
For each selectedprobe set, the concordance index (C-index)
was used to evaluate the predictive accuracy in survival anal-
ysis, where an index of 1.0 is perfect discrimination.26365
Li et alGene Expression Manipulations
Sustained knockdown of programmed cell death protein
4 (PDCD4) or Kruppel-like factor 6 (KLF6) in RWPE-1
cells was achieved by retrovirus or lentivirus-mediated
RNA interference (RNAi) using oligonucleotide sequences
previously described27 in the pSUPER.retro.neo system
(OligoEngine, Seattle, WA) or validated short hairpin RNA
oligonucleotides (MISSION shRNA lentiviruses). Ampho-
tropic retrovirus was produced in Phoenix ampho cells
(a gift from Garry Nolan, Stanford University), with pack-
aging vectors pCgp and pVSV-G to boost viral titer.
IHC Data
Formalin-ﬁxed, parafﬁn-embedded (FFPE) tissues of human
PCA from 61 patients who underwent radical prostatectomy
at Chimei FoundationalMedical Center (theCFMCcohort) or
50 patients at Mackay Memorial Hospital were acquired
and used in conformity with Institutional Review Boarde
approved protocols (Table 1). The biochemical recurrence of
PCAwas deﬁned as a prostate-speciﬁc antigen (PSA) level of
at least 0.4 ng/mL or two consecutive PSA values of
0.2 ng/mL and increasing.28 Tissue sections were deparafﬁ-
nized, hydrated, and immersed in citrate buffer at pH 6.0 for
epitope retrieval in a microwave. Endogenous peroxidase
activity was quenched in 3% hydrogen peroxidase for 15
minutes, and slides were then incubated with 10% normal
horse serum to block non-speciﬁc immunoreactivity. The
antibody was subsequently applied and detected by using the
DAKOEnVision kit (Dako, Carpinteria, CA). The antibodies
used include anti-PDCD4 (1:4000, clone EPR3431), anti-
KLF6 (1:50, polyclonal), and antieATP-binding cassette
transporter 8 (ABCG1; 1:500, clone EP1366Y) (all from
Epitomics, Burlingame, CA). All of the immunohistochem-
ical (IHC) staining was evaluated by two expert pathologists
(C.-F.Li and C.-K. Chen), and the staining patterns were
quantiﬁed using the histological score (H-score).29
Statistical Analysis
We used the statistical programming language R version
2.14.0 (http://cran.r-project.org) and SPSS software versionTable 1 Patient Characteristics
Clinical cohort BWH group (n Z 50) SU/KI/JH
Mean (SD) age (years) 59.4 (6.8) 59.0 (6.
Gleason score
4-7 46 (92.0) 22 (75.
8-9 4 (8.0) 7 (24.
Mean (SD) baseline PSA (ng/mL) 8.3 (5.8) NA
Tumor stage
I-II 30 (60.0) 19 (65.
III 20 (40.0) 10 (34.
Recurrence 9 (18.0) 7 (24.
Medium time to recurrence (months) 42.9 11.5
MMH, Mackay Memorial Hospital; NA, not available.
36610.0 (SPSS, Chicago, IL), to conduct the statistical analysis of
data. A two-tailed Student’s t-test was used for simple
signiﬁcance testing, and two-tailed Pearson tests were used for
correlation analysis.C-statistics analysis was conducted using
the R survcomp package. A cutoff value that best discrimi-
nates between groupswith respect to outcomewas determined
using the maximal Youden’s index.30 Survival curves were
generated using the Kaplan-Meier method. The curves were
plotted and compared using the log-rank test using GraphPad
Prism software version 5.02 (GraphPad Software, La Jolla,
CA). Statistical signiﬁcance was considered if P < 0.05.Results
Molecular and Functional Proﬁling of Prostatic Acinar
Morphogenesis
The study of tissue-speciﬁc differentiation and tumorigen-
esis was greatly enhanced by the exploitation of 3D orga-
notypic culture assays that use an rBM to recapitulate
glandular-like tissues ex vivo.5,31e34 Therefore, we applied
this 3D rBM assay to gain molecular insight into prostatic
epithelial cell morphogenesis and transformation. We noted
that PrECs within 3D rBM grew rapidly within the ﬁrst few
days and formed small cellular aggregates (Figure 1A).
After prolonged culture (7 to 8 days), most of the colonies
assembled polarized, growth-arrested structures with an
acinus-like architecture that was reminiscent of normal
prostatic glands or differentiated low-grade PCA (Figure 1,
A and B). Confocal imaging of spheroids stained for the
polarity markers GM130 and a6(b4) integrin conﬁrmed that
these structures were composed of a single layer of cells
with apico-basal polarity that surrounded a hollow central
lumen (Figure 1A). Colonies of the immortalized prostate
epithelial cell line, RWPE-1 cells,22 embedded within rBM
similarly yielded structurally differentiated acini. By
contrast, malignant PCA cells, such as androgen-sensitive
LNCaP cells, formed continuously growing, disorganized,
and nonpolarized colonies that were morphologically
indistinguishable from high-grade PCA (Figure 1, A and B).
After having recapitulated the acinar morphogenetic
process of prostate epithelium, we next analyzed the geneU group (n Z 29) CFMC group (n Z 61) MMH group (n Z 50)
2) 65.1 (5.6) 67.4 (5.4)
9) 29 (47.5) 20 (40.0)
1) 32 (52.5) 30 (60.0)
18.8 (30.8) 15.2 (3.6)
5) 53 (86.9) 42 (84.0)
5) 8 (13.1) 8 (16.0)
1) 11 (18.0) 12 (24.0)
87.9 70.2
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The American Journal of Pathology - ajp.amjpathol.orgexpression patterns that accompanied this morphological
program. Given that RWPE-1 cells showed a similar
morphological behavior in rBM to primary prostate epithelial
cells, we opted to proﬁle the gene expression pattern of this
immortalized prostate epithelial cell line compared with the
gene expression exhibited by colonies of malignant LNCaP
cells.We then conducted comparative transcriptomic analysis
to identify genes whose transcript levels varied considerably
among all of the samples, with a false-discovery rate of
<0.025. We identiﬁed a list of 411 unique genes (447 probe
sets) that showed differential expression during the acinar
differentiation of RWPE-1 cells (Figure 1C). As a compar-
ison, we found surprisingly few transcriptional changes
associated with the growth of LNCaP tumor spheroids, with
only one of the 411 genes exhibiting signiﬁcant expressional
changes. In addition, we found that the transition of RWPE-1
cells from monolayers on rBM-coated plastics to cellular
aggregates formed within 3D rBM was not associated
with signiﬁcant transcriptional alterations in these cells
(Supplemental Figure S1). These results collectively indi-
cated that the developmental process of prostatic glandular
architectures involved distinct transcriptional alterations that
were not shared by the unorganized aggregation of malignant
cells or the transition among different culture contexts.
Next, to understand, at the functional level, the process of
prostatic acinar differentiation, we surveyed the 411 differ-
entially expressed genes for enriched biological processes.
Gene ontology functional clustering analysis revealed that the
genes up-regulated during prostate acinar morphogenesis
were substantially enriched for those related to epithelial and
ectodermal differentiation and maintenance of epithelial
architectures (Supplemental Figure S2). These included the
cytokeratin proteins KRT15, KRT16, and KRT4; the kerati-
nocyte membranous proteins SPRR1B and SPRR1A; the
laminin-5 subunit LAMB3; the gap junction proteins GJB6
and GJB3; the tight junction protein CLDN8; and the
differentiation-associated transcriptional factors KLF4 and
FOXQ1 (Figure 1D). Complementing this result, functional
analysis of these genes by the Ingenuity Pathway Analysis
program revealed that they were enriched for biologicalFigure 1 Proﬁling structural and functional differentiation of prostatic
epithelial cells. A: Representative confocal images of the prostatic orga-
noids formed by primary prostate epithelial PrECs, RWPE-1 cells, or
malignant LNCaP cells in 3D rBM. The structures were immunostained with
basal extracellular membrane receptor a6-integrin (red) and the apical
marker GM130 (green). Nuclei were counterstained with Hoechst 33342
(blue). Scale bar Z 20 mm. B: Representative histological sections (H&E)
of a normal human prostatic gland and low- or high-grade PCA tissues.
Original magniﬁcation, 400. C: Hierarchical clustering of 411 differen-
tially expressed genes (DEGs) during prostatic acinar morphogenesis. The
heat map depicts high (red) and low (green) relative levels of medium-
centered gene expression in log space. D: Fold changes in the transcript
levels of the genes associated with epithelial differentiation or the
hormonal or secretory functions of prostatic glands in RWPE-1 acini or
LNCaP spheroids versus cellular aggregates, as measured by quantitative
real-time RT-PCR analysis. Data are represented as mean  SEM (n Z 3).
*P < 0.05, **P < 0.01, and ***P < 0.001.
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and organ or tissue development (Supplemental Table S1).
Notably and more important, further interrogation of these
genes identiﬁed several factors related to the hormonal and
secretory functions of prostatic glands, including steroid and
progesterone metabolism (HSD11B2 and DHRS9), mucin or
heparin sulfate production (MUC1 andHS3ST1), spermidine/
sperminemetabolism (SAT1), and the gonadal protein (FST );
these factors were profoundly up-regulated in RWPE-1 acini
compared with cell clusters (Figure 1D). We further demon-
strated that these structural and functional genes displayed
similar transcriptional changes during the acinar morphoge-
netic process of primary PrECs (Supplemental Figure S3);
however, they were only minimally altered during the growth
of LNCaP tumor spheroids (Figure 1D). Taken together, these
ﬁndings lend strong support to our tissue organization model
as a valid way to capture the molecular signals speciﬁc to the
structural and functional differentiation processes of prostatic
glands.
Acini-Like PCA Linked to Favorable Clinical Prognosis
Prevailing tumor models suggested that cancer was driven
by the progressive accumulation of perturbations in genes
and pathways that control cell growth and differentiation. In
line with this paradigm, we observed that the genes asso-
ciated with prostatic acinar differentiation were enriched for
those functionally related to cancer [163 (39.7%) of 411
genes] (Supplemental Table S1). This ﬁnding, together with
the biological and prognostic roles of tissue architectural
differentiation in human PCA,5,7 prompted us to posit that
this differentiation-associated molecular proﬁle might carry
signiﬁcant prognostic information for PCA. To test this, we
interrogated a gene expression microarray data set consist-
ing of 50 patients with localized PCA who underwent
radical prostatectomy (the BWH cohort) (Table 1).10 We
determined the degree of resemblance between the patient
tumors and prostatic acini by calculating the correlation
coefﬁcients (racinus) based on the expression of the 411
acinar morphogenesisespeciﬁc genes (Figure 2A). We
designated the tumors with higher racinus acini-like tumors
and found that patients with this type of tumor exhibited
signiﬁcantly lower risk for relapse compared with those with
lower correlation values by Kaplan-Meier analysis (hazard
ratio, 0.078; log-rank test P Z 0.009) (Figure 2B and
Supplemental Table S2). In a multivariate Cox proportional-
hazards analysis, the racinus of the tumors was the only
signiﬁcant predictor of relapse (hazard ratio, 0.173;
P Z 0.016) (Figure 2B and Supplemental Table S3). We
repeated the previously described analysis in an independent
series of 28 PCA tumors (the SU/KI/JHU cohort)
(Table 1)16 with similar clinical (age and recurrence rate)
and pathological (Gleason score, PSA, and stage) features
with those tumors in the BWH cohort (P > 0.05 by t-test or
Fisher’s exact test). We found that the patients with
acini-like tumors fared better than those with lower racinus in368this validation set (hazard ratio, 0.041; log-rank test
P Z 0.032) (Figure 2C and Supplemental Table S2).
Multivariate analysis conﬁrmed that racinus provided inde-
pendent prognostic information in PCA, whereas the Glea-
son score was only marginally prognostic in this cohort
(Figure 2C and Supplemental Table S3).
After having demonstrated the prognostic value of the
gene expression proﬁleeassociated prostatic acinar mor-
phogenesis, we next asked if comparison among the
molecular characteristics of malignant PCA architectures or
microtumors formed in 3D organotypic culture might also
provide prognostic information to PCA. To this end, we
grew different androgen-sensitive and androgen-insensitive
PCA cell lines in 3D rBM and proﬁled their gene expres-
sions. Surprisingly, none of the gene sets identiﬁed by
comparing these prostate microtumors had signiﬁcant
correlations with the prognosis of patients with PCA
(Supplemental Figure S4). These data suggested that the
molecular variations among developed prostate architec-
tures might provide less prognostic information than those
associated with the differentiation process of prostatic
glandular architectures.Identiﬁcation of Tissue ArchitectureeSpeciﬁc
Prognostic Markers
The marked prognostic value of a prostatic acinar morpho-
genesiseassociated expression proﬁle in human PCA
raised the possibility that this proﬁle might provide an
informative basis for identifying markers with strong prog-
nostic value. Thus, we mapped the 411 genes to the tumor
transcriptome of the BWH data set and constructed a recur-
rence score (RS) based on the Cox model to predict the
occurrence of tumor relapse. The performance in the prog-
nostic prediction, as assessed by the C-index, reached
a plateau when a set of 12 genes was selected (Figure 3A).
Most of the genes in this set, including sialyltransferase 7B
(ST6GALNAC2),ABCG1, biotinidase (BTD),PDCD4,KLF6,
insulin receptor substrate 1 (IRS1), zinc ﬁnger protein 185
(ZNF185), annexin A11 (ANXA11), dual-speciﬁcity phos-
phatase 2 (DUSP2), Kruppel-like factor 4 (KLF4), and des-
mocollin 2 (DSC2), were up-regulated in prostatic acini and
were associated with lower risks of disease relapse
(Supplemental Table S4). These genes exhibited tissue
architectureedependent modulation of gene expression
(Supplemental Figure S5), and many of them might function
as candidate tumor suppressors, according to published bio-
logical studies.10,35e40 More important, an RS calculated
based on the expression proﬁle of these genes could effec-
tively stratify risk of disease recurrence in independent series
of PCA tumors (Figure 3B). Bymultivariate analyses, this 12-
gene model provided strong and independent prognostic
information to PCA and markedly enhanced the prognostic
accuracy of clinical and pathological variables (Supplemental
Tables S5eS7).10,11,41ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Acini-like PCA has a reduced risk of postoperative disease relapse. A: A schematic representation depicting the derivation of racinus. DEG,
differentially expressed gene. B: Kaplan-Meier survival curves (left panel) comparing relapse-free survival of patients with PCA in the BWH cohort with a high
(acini-like) or low racinus value of their tumors. The P value is calculated using the log-rank test. A harzard ratio (HR) plot (right panel) (with 95% conﬁdence
limits) of disease relapse, according to racinus, age, tumor stage, and PSA or Gleason score in a Cox proportional hazards analysis. C: Kaplan-Meier survival
curves (left panel) comparing relapse-free survival of patients with PCA in the SU/KI/JHU cohort, stratiﬁed according to racinus. An HR plot of disease relapse
(right panel), according to racinus or clinicopathological criteria in a Cox proportional hazards analysis. *P < 0.05.
Acinar Morphogenesis Signature in PCANext, seeking to determine whether the prognostic corre-
lation of these genes could be observed at the protein and the
tissue levels, we focused on three top-ranked genes with
validated antibodies for IHC, including PDCD4, KLF6, and
ABCG1. We surveyed their tissue expressions by performing
IHC staining of the FFPE tumor tissue sections from a cohort
of 61 patients with PCA who underwent radical prostatec-
tomy (the CFMC cohort) (Table 1 and Figure 3C). Indeed,
the staining intensities of PDCD4, as assessed by the H-score
(Supplemental Figure S6), showed strong negative associa-
tions with risk of postoperative biochemical recurrence by
Kaplan-Meier analysis (log-rank test P 0.001) (Figure 3D).
We also found that tumors that stained intensely with
KLF6 or ABCG1 were associated with signiﬁcantly longer
recurrence-free survival compared with those with lower
staining intensities (log-rank test P  0.001) (Figure 3D).
Multivariate analyses showed that the tissue expression level
of each of these genes was prognostic, independent of clin-
ical criteria or Gleason score (Supplemental Table S8).The American Journal of Pathology - ajp.amjpathol.orgPCDC4 and KLF6 as Regulators and Surrogate Markers
of Prostatic Tissue Architectures
Recent studies demonstrated that KLF6 or PDCD4 regu-
lated the expression of the cell adhesion molecule, E-cad-
herin,36,37 raising a possibility of their potential roles in
the maintenance of epithelial tissue architecture. Multiple
lines of evidence supported this possibility. First, in human
PCA tissues, the staining intensities of PDCD4 or KLF6
were inversely correlated with Gleason score (P < 0.05)
(Figure 4A). Second, we demonstrated that the expression
of PDCD4 or KLF6 was reciprocally linked to the state of
tissue differentiation (Figure 4B). Speciﬁcally, the transcript
levels of PDCD4 or KLF6 increased signiﬁcantly during the
acinar morphogenetic process of prostate epithelial cells.
However, structural disruption of prostatic acini by func-
tional inhibition of E-cadherin prevented the increase in
their expressions. Moreover, the context-dependent regula-
tion of PDCD4 or KLF6 expression was reversible, because369
Figure 3 Identiﬁcation of tissue architectureespeciﬁc prognostic markers of PCA. A: Selection of a 12-gene set based on the distribution of the
concordance index in the prediction of risk of disease relapse. B: Kaplan-Meier survival curves comparing relapse-free survival of patients with PCA in the BWH
cohort or the SU/KI/JHU cohort. The patients were stratiﬁed into two groups based on the RS, calculated based on the expression proﬁle of the 12-gene set as
selected in A. The P values are calculated using the log-rank test. C: Representative immunostaining of PDCD4, KLF6, and ABCG1 in PCA tissues. Original
magniﬁcation, 400. Tumors with high (left panels) or low (right panels) staining intensities of the respective markers are shown. D: Kaplan-Meier survival
curves (top panels) comparing recurrence-free survival of patients with PCA in the CFMC cohort, stratiﬁed according to the staining intensities of PDCD4, KLF6,
or ABCG1. The P values are calculated using the log-rank test. Hazard ratio (HR) plots (with 95% conﬁdence limits) of disease relapse (bottom panels),
according to the staining intensities of PDCD4, KLF6, or ABCG1, or clinicopathological criteria in a Cox proportional hazards analysis. *P < 0.05.
Li et althe cellular aggregates recovered from prostatic acini had
similar expression levels of PDCD4 or KLF6 with those
measured in the original (ie, primary) cellular aggregates.
Third, by using retrovirus-mediated RNAi (Figure 4C), we
found that selective down-regulation of the expression of
either PDCD4 or KLF6 could profoundly cripple the ability
of RWPE-1 cells to form polarized prostatic cysts in 3D
rBM (Figure 4D).
The critical roles of PDCD4 and KLF6 in the regulation of
prostatic tissue architectures prompted us to investigate if
they could together form a signature that was prognostic
of disease recurrence in human PCA. Indeed, an RS calcu-
lated based on the staining intensities of PDCD4, KLF6,
and ABCG1 could stratify the risk of postoperative relapse,
with a remarkable accuracy in the CFMC cohort (C-index
Z 0.951) (Figure 5 and Supplemental Table S9), and
greatly outperformed a combined clinical model (P Z
0.001) (Supplemental Table S10). In a multivariate Cox
proportional-hazards analysis, the three-gene modelebased
RS was the only signiﬁcant prognostic predictor (hazard370ratio, 22.591; P Z 0.004) (Supplemental Table S11). The
prognostic prediction could also achieve high accuracy when
the transcript abundance levels of these makers were used
(C-index Z 0.939; the BWH cohort) (Figure 5 and
Supplemental Tables S10 and S11). To further verify the
clinical utility of this three-gene prognostic model, we per-
formed IHC staining of PDCD4, KLF6, and ABCG1 in
another independent series of 50 PCA tumors (the Mackay
Memorial Hospital cohort) (Table 1). Indeed, an RS calcu-
lated based on the staining intensities of these genes could
stratify patients into prognostic groups (hazard ratio, 9.7;
log-rank P Z 0.0009) (Figure 5 and Supplemental Table
S10). We conﬁrmed that the three-gene modelebased RS
greatly outperformed a combined clinical model (P< 0.001)
(Supplemental Table S10) and was a strong and independent
predictor of postoperative relapse in this validation data set
(hazard ratio, 20.234; PZ 0.002) (Supplemental Table S11).
Collectively, the robust prognostic utility of PDCD4 and
KLF6 and their functional importance in prostate epithelial
architectures established them as surrogate markers of tissueajp.amjpathol.org - The American Journal of Pathology
Figure 4 The roles of PDCD4 and KLF6 in prostatic tissue architectures.A: Gleason scores of the PCA tumors in the CMFC cohort with high (black bars) or low (white
bars) staining intensities of PDCD4 or KLF6. Data are represented as mean SEM. *P< 0.1, **P< 0.05. B: Schematic representation of the experimental protocol for
growing different prostatic tissue architectures. RWPE-1 cells were grown in 3D rBM as primary cellular aggregates (ﬁrst aggregates) or acini (left panel). The
formation of acinar architecture was abrogated by incorporating a function-blocking antibody of E-cadherin (antieE-cad) in thematrices. Alternatively, the cells were
recovered from differentiated acini by enzymatic digestion and re-embedded in 3D rBM to allow for the growth of secondary cellular aggregates (second aggregates).
The transcript abundance levels of PDCD4 and KLF6 in different prostatic tissue architectures, as measured by quantitative real-time RT-PCR analysis (right panel).
Data are represented asmean SEM (nZ 3). **P< 0.05, ***P< 0.01 versusﬁrst aggregates. C: Immunoblotting showing the effect of RNAi-mediated knockdownof
PDCD4 or KLF6 in RWPE-1 cells. b-Tubulin was included as a loading control. D: Representative confocal images of the prostatic organoids formed by PDCD4- or KLF6-
deﬁcient RWPE-1 cells or the control RNAi cells in 3D rBM (left panel). The structures were immunostained with basal extracellular membrane receptor a6-integrin
(red). Nucleiwere counterstainedwithHoechst 33342 (blue). Scale barZ20mm.Percentage of polarizedorganoids, as quantiﬁedby visual examination and counting
under a ﬂuorescence microscope (right panel). Data are represented as mean  SEM (nZ 25). ****P < 0.001 versus control.
Acinar Morphogenesis Signature in PCAdifferentiation that were linked to clinical outcomes of
patients with PCA.
Discussion
Molecular characterization of malignant tumors can aid
disease classiﬁcation and the prognostic prediction of the
patients.14,42,43 Herein, we summarize our ﬁndings, which
exploited the experimental merits of a physiologically rele-
vant model of tissue differentiation, to identify a molecular
signature that reﬂects prostate tumors with a better prognosis.
Our signature, which was informed by the gene expression
proﬁle of differentiated prostate epithelial acini, speciﬁcally
identiﬁes prostate tumors with a more differentiated pheno-
type. We used our architecture-related signature to identify
a subset of human PCA that exhibits a favorable outcome.
This novel and biology-informed molecular classiﬁcationThe American Journal of Pathology - ajp.amjpathol.orgsystem considerably outperforms clinical and pathological
criteria and improves prognostic prediction in several inde-
pendent cohorts of patients with PCA. Thus, our results offer
critical insight toward the functional link between tissue
architectures and PCA in human tissue and, to our knowledge,
provide the ﬁrst ever set of biologically relevant molecular
markers that have potential clinical utility.
One of the major challenges in the care of patients with
early-stage PCA is the ability to identify those patients who
are at risk for early relapse after surgery. Clinical and
pathological criteria fail to provide an accurate prediction of
tumor relapse. Accordingly, there have been numerous
attempts to improve prognostic prediction by constructing
accurate proﬁles of the molecular characterizations of the
excised prostate tumors, with varying success.10,11 For
instance, correlating the tumor transcriptome data with
clinical outcome data in a relatively small cohort (n Z 21)371
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Li et alof patients with PCA, Singh et al10 demonstrated that the
expression pattern of a set of ﬁve gene markers in the
excised primary tumors could be used to accurately predict
the clinical behaviors of PCA. In another example,
comparative transcriptomic analysis on recurrent or nonre-
current human PCA and metastatic xenografted tumors in
mice resulted in the identiﬁcation of several PCA gene
signatures that possessed validated prognostic values.11
More recently, Malhotra et al41 developed a proliferative
index of PCA based on the IHC staining patterns of three
proliferation-related gene markers, including MKI67,
TOP2A, and E2F1, which improved prognostic prediction in
a cohort of 139 patients with PCA. However, unfortunately,
these molecular markers have yet to be adopted in clinical
practice, in part because of the pressing need for additional
large-scale performance testing, but also possibly because of
their lack of mechanistic insight and/or biological demon-
strated relevance to prostate tissue transformation. In the
present study, we identiﬁed the ﬁrst biologically tractable
prognostic signature of PCA, which, in addition, presents
a plausible mechanism linked to tissue-speciﬁc differentia-
tion and adhesion-dependent tissue architecture. Our
signature supplements the Gleason score and can function as
a viable prognostic predictor of patients with PCA. More-
over, our signature can provide a much-needed means to
molecularly deﬁne differentiated PCA. Presumably, this
knowledge-based classiﬁcation system may improve the372prognostic prediction of PCA and permit the development
of rational personalized therapeutic strategies to treat PCA.
By using a 3D morphogenesis assay, we demonstrated that
the expression of prostatic acinar morphogenesis-associated
genes is tightly regulated by tissue organization. Interestingly,
some of these genes passively respond to tissue architecture
cues and are reciprocally linked to the assembly of
tissue organization. Thus, we found that down-regulating
PDCD4 or KLF6 in prostate epithelial cells disrupted their
acinar morphogenesis. Such a functional role for these
differentiation-associated genes with PCA behavior may
explain their signiﬁcant correlation to PCA Gleason score and
the clinical prognosis of patients with PCA. For instance, the
genePDCD4 encodes a candidate tumor suppressor that targets
translation initiation44 and reduces the growth of PCA cells
through down-regulation of Y-boxebinding protein-1 expres-
sion.45 ThegeneKLF6 encodes a zincﬁnger transcription factor
that can up-regulate p21 and is mutated in 70% of human PCA
and lost in high-grade tumors.35,46 Interestingly and more
important, bothKLF6 andPDCD4 induce expression of the cell
adhesion molecule, E-cadherin,36,37 providing a mechanistic
explanation of their roles in tissue architecture. Other constit-
uent genes in the acinar morphogenesiseassociated 12-gene
signature, such as KLF4 and IRS1, may also regulate prostate
epithelial architecture by reducing cell migration/invasion or
increasing extracellular membraneedependent adhesion in
prostate cancer cells.38,40 On the other hand, there is abundantajp.amjpathol.org - The American Journal of Pathology
Acinar Morphogenesis Signature in PCAevidence that supports a prognostic role of the other genes in the
signature, although the mechanisms underlying their pathoge-
netic roles in PCA are less clear. For instance, the only secreted
protein in the signature, biotinidase (BTD), was identiﬁed as
a serum biomarker for Gleason score prediction in PCA.47 The
gene DUSP2 encodes a dual-speciﬁcity phosphatase that is
a negative regulator of mitogen-activated protein kinases and is
markedly reduced in humanPCA tissues.39Finally, althoughno
report has directly linked the top-ranked gene in the signature,
ST6GALNAC2, to the prognosis of PCA, another sialyl-
transferase, sialyltransferase 1, is the major gene marker in the
ﬁve-gene signature identiﬁed by Singh et al.10
The clinical utility of biomarkers can be greatly enhanced if
they can be detected in FFPE tissue sections that are routinely
available for pathological examination.Becausewe noted that
most of the gene markers in our 12-gene signature exhibit
signiﬁcant prognostic value in PCA, we believe that it may be
feasible to identify a speciﬁc combination of thesemarkers for
clinical prediction of patient prognosis. In particular, our data
indicate one particular combination, consisting of PDCD4,
KLF6, and ABCG1, and we showed that this combination of
markers can be readily detected by IHC and can provide
strong and robust prognostic information for PCA.We further
demonstrated that mRNA levels of these markers can provide
equally accurate prognostic prediction in patients with PCA,
thereby providing an alternate strategy to screen for prog-
nostic markers in PCA patient tissue. By using either IHC or
RNA screening approaches, it is feasible to conduct a large-
scale validation of our prognostic signature using frozen
tumor materials (for mRNA) or FFPE tissues (for IHC
staining) collected from either prospective or retrospective
clinical trials. Furthermore, aside from this three-gene
combination, our preliminary analysis also showed that any
two of these genes (eg, PDCD4 versus KLF6 or PDCD4
versus ABCG1) function as a robust prognostic predictor with
high accuracy in independent patient cohorts (C-index up to
0.915; data not shown). Suchﬁndings imply that other clinical
useful combinations of these architecture-speciﬁc markers
may exist and merit further evaluation.
In summary, our results illustrate that interrogation of the
transcriptional program associated with prostate acinar
differentiation is able to be exploited to generate a strong and
robust prognostic predictor for human PCA. The architecture-
related gene signature is strong and independent of clinico-
pathological criteria, reinforcing the idea that biomarkers
constructed based on crucial tumor biological characteristics
could signiﬁcantly improve disease classiﬁcation and outcome
prediction.Whether the same approach could be applied to the
identiﬁcation of prognostic markers in more advanced PCA or
other types of glandular cancers awaits further investigation.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2012.10.024.The American Journal of Pathology - ajp.amjpathol.orgReferences
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